Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. Tan RSYC, et al. Among authors: yap ys. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. BMC Med. 2022. PMID: 35296300 Free PMC article.
Association of common genetic variants with breast cancer risk and clinicopathological characteristics in a Chinese population.
Chan M, Ji SM, Liaw CS, Yap YS, Law HY, Yoon CS, Wong CY, Yong WS, Wong NS, Ng R, Ong KW, Madhukumar P, Oey CL, Tan PH, Li HH, Ang P, Ho GH, Lee AS. Chan M, et al. Among authors: yap ys. Breast Cancer Res Treat. 2012 Nov;136(1):209-20. doi: 10.1007/s10549-012-2234-y. Epub 2012 Sep 11. Breast Cancer Res Treat. 2012. PMID: 22965832
Outcome after neoadjuvant chemotherapy in Asian breast cancer patients.
Lim LY, Miao H, Lim JS, Lee SC, Bhoo-Pathy N, Yip CH, Taib NA, Chan P, Tan EY, Lim SH, Lim GH, Woo E, Tan YS, Lee JA, Wong M, Tan PH, Ong KW, Wong FY, Yap YS, Hartman M. Lim LY, et al. Among authors: yap ys. Cancer Med. 2017 Jan;6(1):173-185. doi: 10.1002/cam4.985. Epub 2016 Dec 20. Cancer Med. 2017. PMID: 28000426 Free PMC article.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore Chinese.
Chan CHT, Munusamy P, Loke SY, Koh GL, Yang AZY, Law HY, Yoon CS, Wong CY, Yong WS, Wong NS, Ng RCH, Ong KW, Madhukumar P, Oey CL, Ho GH, Tan PH, Tan MH, Ang P, Yap YS, Lee ASG. Chan CHT, et al. Among authors: yap ys. Oncotarget. 2018 Jan 31;9(16):12796-12804. doi: 10.18632/oncotarget.24374. eCollection 2018 Feb 27. Oncotarget. 2018. PMID: 29560110 Free PMC article.
126 results